scPharmaceuticals Inc. revised earnings guidance for the year 2022. Based on its current operating plan, the Company has adjusted its 2022 net loss to $38 to $41 million, a decrease over prior guidance of $43 to $48 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.88 USD | -12.61% | -3.24% | -38.12% |
05-14 | Transcript : ScPharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | ScPharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.12% | 160M | |
+43.64% | 749B | |
+39.42% | 605B | |
-6.58% | 351B | |
+19.72% | 328B | |
+8.78% | 292B | |
+11.92% | 216B | |
-2.62% | 214B | |
+0.03% | 167B | |
+6.13% | 165B |
- Stock Market
- Equities
- SCPH Stock
- News scPharmaceuticals Inc.
- ScPharmaceuticals Inc. Revises Earnings Guidance for the Year 2022